| 000 | 01787 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513030220.0 | ||
| 264 | 0 | _c19960111 | |
| 008 | 199601s 0 0 eng d | ||
| 022 | _a0028-4793 | ||
| 024 | 7 |
_a10.1056/NEJM199601043340101 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcGuire, W P | |
| 245 | 0 | 0 |
_aCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cJan 1996 |
||
| 300 |
_a1-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aHoskins, W J | |
| 700 | 1 | _aBrady, M F | |
| 700 | 1 | _aKucera, P R | |
| 700 | 1 | _aPartridge, E E | |
| 700 | 1 | _aLook, K Y | |
| 700 | 1 | _aClarke-Pearson, D L | |
| 700 | 1 | _aDavidson, M | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 334 _gno. 1 _gp. 1-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJM199601043340101 _zAvailable from publisher's website |
| 999 |
_c7494031 _d7494031 |
||